BR1015-3

DRUG4 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

Essential Hypertension

Phase 1

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions

CompletedNCT06744439

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2025-01-09End: 2025-03-16Updated: 2025-04-09

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions

CompletedNCT06744426

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2025-01-04End: 2025-03-12Updated: 2025-04-09

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions

Not yet recruitingNCT07421414

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2026-04-19End: 2026-06-17Target: 48Updated: 2026-02-19

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions

Not yet recruitingNCT07421401

Boryung Pharmaceutical Co., LtdEssential Hypertension

Start: 2026-04-13End: 2026-06-11Target: 58Updated: 2026-02-19